Targeting WEE1 to enhance conventional therapies for acute lymphoblastic leukemia.

ABSTRACT:

Background

Despite the recent progress that has been made in the understanding and treatment of acute lymphoblastic leukemia (ALL), the outcome is still dismal in adult ALL cases. Several studies in solid tumors identified high expression of WEE1 kinase as a poor prognostic factor and reported its role as a cancer-conserving oncogene that protects cancer cells from DNA damage. Therefore, the targeted inhibition of WEE1 kinase has emerged as a rational strategy to sensitize cancer cells to antineoplastic compounds, which we evaluate in this study.

Methods

The effectiveness of the selective WEE1 inhibitor AZD-1775 as a single agent and in combination with different antineoplastic agents in B and T cell precursor ALL (B/T-ALL) was evaluated in vitro and ex vivo studies. The eff

SUBMITTER: Ghelli Luserna Di Rora A 

PROVIDER: S-EPMC6090987 | biostudies-literature | 2018 Aug

REPOSITORIES: biostudies-literature